References
- Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241–7.
- Alimchandani M, Wang ZF, Miettinen M. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: A study of 146 cases. Appl Immunohistochem Mol Morphol 2014;22:358–62.
- Aggerholm-Pedersen N, Baerentzen S, Holmberg Jorgensen JP, Safwat A. A rare case of CD30(+), radiation-induced cutaneous angiosarcoma misdiagnosed as T-cell lymphoma. J Clin Oncol 2011;29:e362–4.
- Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008;44: 2433–6.
- Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996;77:2400–6.
- Young RJ, Natukunda A, Litiere S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 2014;50:3178–86.
- Weed BR, Folpe AL. Cutaneous CD30-positive epithelioid angiosarcoma following breast-conserving therapy and irradiation: A potential diagnostic pitfall. Am J Dermatopathol 2008;30:370–2.
- Lin CF, DeFrias D, Lin X. Epithelioid angiosarcoma: A neoplasm with potential diagnostic challenges. Diagn Cytopathol 2010;38:154–8.
- Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486–97.
- Ansell SM. Brentuximab vedotin. Blood. 2014.